ChemoCentryx, Inc.
(NASDAQ : CCXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 20.57%329.630.0%$4354.99m
BNTXBioNTech SE 14.19%348.000.0%$1400.74m
NVAXNovavax, Inc. 8.95%217.9778.2%$1098.56m
AMGNAmgen, Inc. -1.41%201.091.4%$565.85m
LGVNLongeveron Inc. -27.49%30.670.0%$559.00m
REGNRegeneron Pharmaceuticals, Inc. -0.75%643.352.7%$495.48m
GILDGilead Sciences, Inc. 0.29%70.271.0%$491.04m
SNSSSunesis Pharmaceuticals, Inc. -8.16%4.840.7%$338.33m
VRTXVertex Pharmaceuticals, Inc. -1.42%183.591.9%$332.99m
OCGNOcugen, Inc. -9.16%6.450.0%$317.79m
ILMNIllumina, Inc. 1.16%369.793.3%$291.39m
BIIBBiogen, Inc. -2.89%242.901.8%$257.70m
BMRNBioMarin Pharmaceutical, Inc. -2.22%87.584.2%$157.02m
EXASEXACT Sciences Corp. -2.99%85.4618.0%$156.18m
INCYIncyte Corp. 2.46%68.382.4%$147.61m

Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.